Gilead Faces Pricing Controversy Over HIV Drug Lenacapavir in Latin America
Gilead Sciences is facing criticism over the pricing of its HIV prevention drug, lenacapavir, in Latin America. Despite the drug's potential to significantly reduce HIV infections, its high cost in countries like Brazil, Mexico, Argentina, and Peru has sparked protests. These countries, classified as 'upper-middle income,' do not qualify for the reduced price offered to lower-income nations. Activists and officials argue that the pricing strategy is unjust, given the drug's life-saving potential. Brazil's health minister has criticized Gilead for demanding prices significantly higher than those in other countries with similar economic status. 
